Objective: To assess the effect of treatment with endothelin-receptor anatagonists on patients with Eisenmenger syndrome, by monitoring oxygen saturation, exercise capacity and echocardiography.
Methods: A total of 14 pediatric patients diagnosed with Eisenmenger syndrome were evaluated clinically by systemic pulse-oximetry, 6-minute walk test and by echocardiography at the beginning of pulmonary vasodilator treatment with endothelin-receptor antagonist, at 3 and 6 months after treatment initiation.
Results: NYHA functional class, systemic arterial blood saturation and distance walked in 6 minutes improved after 3 and 6 months of pulmonary vasodilator treatment. In our study we observed that Tei index right ventricle has improved after 3 months of therapy. We found no statistically significant changes in other ecocardiographic parameters of pulmonary hypertension evaluation.
Conclusions: Endothelin-receptor antagonist improved exercise capacity and hemodynamics, without compromising peripheral oxygen saturation.
Study perfomed in the research project MAMI no. 41-042/2007, financed by the Roumanian Ministry of Education, Research and Youth
Evaluation of Pulmonary Vasodilator Therapy with Endothelin-Receptor Antagonist in Eisenmenger Syndrome
Full text: PDF
